<br>        Inclusion Criteria:<br><br>          -  Received a kidney transplant = 9 weeks at time of Screening and = 24 months before<br>             first dose<br><br>          -  May be the first kidney transplant or a repeat kidney transplant.<br><br>          -  Subjects with a functional, stable kidney transplant, defined as MDRD estimated<br>             glomerular filtration rate (eGFR) = 30 mL/min/1.73 m² (chromic kidney disease stage 3<br>             or better) at Screening.<br><br>          -  Men or women = 18 years at the start of Screening (ie, time of informed consent).<br><br>          -  Corrected total serum calcium > 10.5 mg/dL (2.63 mmol/L), defined as the mean of 2<br>             values in Screening period.<br><br>          -  iPTH > 100 pg/mL (10.6 pmol/L), during the Screening period (obtained at either Screen<br>             1 or Screen 2).<br><br>        Exclusion Criteria:<br><br>          -  Received cinacalcet therapy post-transplant for more than 14 days cumulatively<br>             post-transplant. If cinacalcet therapy was received for a total of 14 days or less<br>             post-transplant, there must be a 4-week washout before subject is eligible for<br>             screening (Note: This does not exclude pre-transplant use of cinacalcet).<br><br>          -  Anticipated parathyroidectomy within 6 to12 months after Randomization.<br><br>          -  Ongoing therapy with bisphosphonates or use within 6 months prior to Screening.<br><br>          -  Ongoing use of 1,25-dihydroxyvitamin D3 (including other active vitamin D metabolites<br>             or analogues) or use within 30 days prior to Screening.<br><br>          -  Ongoing use of calcium supplements or use within 30 days prior to Screening.<br><br>          -  Ongoing use of phosphate binders (calcium or non-calcium containing) or use within 30<br>             days prior to Screening.<br><br>          -  Ongoing use of a thiazide diuretic.<br><br>          -  Subjects with a history of seizures who had a seizure within the 3 months prior to<br>             Randomization, which required adjustments to the seizure medication.<br><br>          -  Acute Kidney Injury (AKI) or renal biopsy within 6 weeks prior to Screening, unless it<br>             is an institutional protocol-driven biopsy.<br>